Updates in triple-negative breast cancer, patient feedback guides prostate cancer treatment — top stories in hematology/oncology
Healio presented updates in research and treatment of triple-negative breast cancer, an aggressive subtype that accounts for approximately 15% of all breast cancer cases. It was the top story in hematology/oncology last week.
In another top story, Healio spoke with Karen E. Hoffman, MD, MHSc, MPH, about how patient-reported outcomes could help guide the course of treatment for localized prostate cancer.
Read these and more top stories below:
Eight important updates for Triple-Negative Breast Cancer Awareness Day
Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases. The aggressive subtype is so named because the estrogen, progestin and HER2 receptors are not expressed. Most approved therapies target these receptors, making triple-negative disease difficult to treat and leading to poor prognosis. Read more.
Patient-reported outcomes could help guide selection of treatment for localized prostate cancer
Patient-reported adverse effect profiles 5 years after contemporary treatment for localized prostate cancer could help inform treatment choices for this patient population, according to study results published in JAMA. Read more.
FDA approves Sarclisa regimen for adults with advanced multiple myeloma
The FDA approved isatuximab-irfc in combination with pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who received at least two previous therapies, including lenalidomide and a proteasome inhibitor. Read more.
Venetoclax regimen fails to extend OS in newly diagnosed AML
A randomized phase 3 study designed to evaluate the addition of venetoclax to low-dose cytarabine failed to show significant OS improvement among patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy, according to the agent’s manufacturer. Read more.
Targeted treatments extend survival in pancreatic cancer
A precision medicine approach to therapy significantly extended survival for patients with pancreatic cancer compared with standard chemotherapy, according to results of a retrospective study published in The Lancet Oncology. Read more.